USPlabs Crafts DMAA Defense As Shield Against Further Damage

USPlabs’ compliance with FDA’s request to cease marketing DMAA-containing products came following lengthy and detailed responses to the agency that could shield the firm from class action lawsuits and state investigations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America